Loading...

Oncimmune Holdings

BST:OCY
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
OCY
BST
£63M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Oncimmune Holdings Plc, an early cancer detection company, develops and commercializes products to diagnose cancer in the United Kingdom and North America. The last earnings update was 67 days ago. More info.


Add to Portfolio Compare Print
OCY Share Price and Events
7 Day Returns
-5.5%
BST:OCY
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-22.4%
BST:OCY
-10.2%
DE Biotechs
-6%
DE Market
OCY Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Oncimmune Holdings (OCY) -5.5% 10.6% -7.1% -22.4% - -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • OCY underperformed the Biotechs industry which returned -10.2% over the past year.
  • OCY underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
OCY
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Oncimmune Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Oncimmune Holdings. This is due to cash flow or dividend data being unavailable. The share price is €1.04.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Oncimmune Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Oncimmune Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:OCY PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-11-30) in GBP £-0.12
AIM:ONC Share Price ** AIM (2019-04-18) in GBP £0.99
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Oncimmune Holdings.

BST:OCY PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:ONC Share Price ÷ EPS (both in GBP)

= 0.99 ÷ -0.12

-8.08x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Oncimmune Holdings is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Oncimmune Holdings is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Oncimmune Holdings's expected growth come at a high price?
Raw Data
BST:OCY PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -8.08x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
47.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Oncimmune Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Oncimmune Holdings's assets?
Raw Data
BST:OCY PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-11-30) in GBP £0.16
AIM:ONC Share Price * AIM (2019-04-18) in GBP £0.99
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
BST:OCY PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:ONC Share Price ÷ Book Value per Share (both in GBP)

= 0.99 ÷ 0.16

6.24x

* Primary Listing of Oncimmune Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Oncimmune Holdings is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Oncimmune Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Oncimmune Holdings has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Oncimmune Holdings expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Oncimmune Holdings expected to grow at an attractive rate?
  • Unable to compare Oncimmune Holdings's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Oncimmune Holdings's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Oncimmune Holdings's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
BST:OCY Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:OCY Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 47.9%
BST:OCY Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 99.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:OCY Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:OCY Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-05-31 15 -1 1
2020-05-31 7 -7 1
2019-05-31 2 -10 1
BST:OCY Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2018-11-30 0 -7 -7
2018-08-31 0 -6 -7
2018-05-31 0 -6 -6
2018-02-28 0 -6 -6
2017-11-30 0 -5 -5
2017-08-31 0 -5 -5
2017-05-31 0 -4 -5
2017-02-28 0 -4 -8
2016-11-30 0 -5 -10
2016-08-31 0 -4 -9
2016-05-31 0 -3 -8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Oncimmune Holdings is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Oncimmune Holdings's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:OCY Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Oncimmune Holdings Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:OCY Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-05-31 -0.01 -0.01 -0.01 1.00
2020-05-31 -0.11 -0.11 -0.11 1.00
2019-05-31 -0.16 -0.16 -0.16 1.00
BST:OCY Past Financials Data
Date (Data in GBP Millions) EPS *
2018-11-30 -0.12
2018-08-31 -0.12
2018-05-31 -0.11
2018-02-28 -0.11
2017-11-30 -0.10
2017-08-31 -0.10
2017-05-31 -0.10
2017-02-28 -0.15
2016-11-30 -0.20
2016-08-31 -0.22
2016-05-31 -0.24

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Oncimmune Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Oncimmune Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Oncimmune Holdings has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Oncimmune Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Oncimmune Holdings's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Oncimmune Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Oncimmune Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Oncimmune Holdings's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Oncimmune Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Oncimmune Holdings Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:OCY Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-11-30 0.28 -7.36 5.60 1.04
2018-08-31 0.26 -6.85 5.25 0.92
2018-05-31 0.24 -6.34 4.90 0.80
2018-02-28 0.21 -5.86 4.41 0.92
2017-11-30 0.18 -5.37 3.93 1.04
2017-08-31 0.20 -5.20 3.93 1.03
2017-05-31 0.22 -5.02 3.93 1.03
2017-02-28 0.24 -7.55 3.91 0.93
2016-11-30 0.27 -10.07 3.89 0.84
2016-08-31 0.35 -9.26 3.94 0.81
2016-05-31 0.43 -8.44 3.98 0.79
2015-05-31 1.35 -2.01 2.11 0.62
2014-05-31 1.06 -1.41 2.58
2013-05-31 1.53 -3.02 3.22
2012-05-31 0.15 -4.44 3.36

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Oncimmune Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Oncimmune Holdings has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Oncimmune Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Oncimmune Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Oncimmune Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Oncimmune Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Oncimmune Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Oncimmune Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Oncimmune Holdings has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Oncimmune Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Oncimmune Holdings has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Oncimmune Holdings Company Filings, last reported 4 months ago.

BST:OCY Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2018-11-30 9.77 0.00 9.05
2018-08-31 9.77 0.00 9.05
2018-05-31 13.56 0.00 12.95
2018-02-28 13.56 0.00 12.95
2017-11-30 6.83 0.20 6.30
2017-08-31 6.83 0.20 6.30
2017-05-31 5.00 0.50 5.08
2017-02-28 5.00 0.50 5.08
2016-11-30 7.43 0.68 7.62
2016-08-31 7.43 0.68 7.62
2016-05-31 9.73 0.89 10.20
2015-05-31 -3.82 4.62 1.34
2014-05-31 -1.81 3.30 1.57
2013-05-31 -0.36 1.32 1.13
2012-05-31 0.59 1.25 2.11
  • Oncimmune Holdings has no debt.
  • Oncimmune Holdings currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Oncimmune Holdings has sufficient cash runway for 1.3 years based on current free cash flow.
  • Oncimmune Holdings has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 27.1% each year.
X
Financial health checks
We assess Oncimmune Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Oncimmune Holdings has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Oncimmune Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Oncimmune Holdings dividends.
If you bought €2,000 of Oncimmune Holdings shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Oncimmune Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Oncimmune Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:OCY Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:OCY Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2021-05-31
2020-05-31
2019-05-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Oncimmune Holdings has not reported any payouts.
  • Unable to verify if Oncimmune Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Oncimmune Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Oncimmune Holdings has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Oncimmune Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Oncimmune Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Oncimmune Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Oncimmune Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Adam Hill
COMPENSATION £333,316
AGE 38
TENURE AS CEO 0.6 years
CEO Bio

Dr. Adam Mark Hill, MB, PhD, has been the Chief Executive Officer at Oncimmune Holdings Plc since September 2018. Dr. Mark also served as Director at Oncimmune Holdings Plc. He served as Chief Medical Officer and Chief Strategy Officer of Oncimmune Holdings Plc since April 9, 2018 until September 2018. He is a dual-qualified Clinician and Engineer, with a career built in industry, academia and practising medicine. During his career, he has held Chief Medical Officer and other senior management roles at private and listed companies, supplemented by advisory and government policy appointments. Most recently, he was Chief Medical Officer and later Chief Strategy Officer of McLaren Applied Technologies. He developed a Digital Therapeutics strategy and grew a team of experienced professionals across Commercial, Product, Programme, Quality and Technical disciplines to deliver against it. Previously, he was Chief Medical Officer at Sectra AB, the listed medical technology and encryption Communications Company, and a Management Consultant with PA Consulting. He graduated from Imperial College London as a Medical Doctor, whilst also earning a PhD in Engineering, attending Imperial College Business School, and the Royal Military Academy Sandhurst. He received his postgraduate clinical training from the Royal College of Surgeons of England, and professional engineering qualification from the Institution of Mechanical Engineers. He has built a portfolio of over 100 academic peer-reviewed, policy and popular-media publications. Currently, he is both a Visiting Professor in Global Health Innovation at Imperial College London, and sits on the Advisory Board of Imperial College Health Partners. Dr. Hill holds Doctor of Medicine, PhD Bioengineering and Bachelor of Science in Engineering. His Past Directorships include DON'T HESITATE TO COPE LIMITED &STRENSON MEDICAL LIMITED. He served as Chief Medical Officer of Sectra Aktiebolag (publ).

CEO Compensation
  • Insufficient data for Adam to compare compensation growth.
  • Adam's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Oncimmune Holdings management team in years:

2.3
Average Tenure
  • The tenure for the Oncimmune Holdings management team is about average.
Management Team

Adam Hill

TITLE
CEO & Director
COMPENSATION
£333K
AGE
38
TENURE
0.6 yrs

Andrew Millet

TITLE
Executive
COMPENSATION
£103K
AGE
51
TENURE
0.3 yrs

Matthew Hall

TITLE
Group Chief Financial Officer
TENURE
0.3 yrs

Laura Peek

TITLE
Principal Scientist & Assistant Lab Director
TENURE
3 yrs

Andrew Stewart

TITLE
General Counsel & Company Secretary
TENURE
0.3 yrs

Andrea Murray

TITLE
Chief Operational Scientist
TENURE
3.6 yrs

Jim Jett

TITLE
Chief Medical Officer of US
TENURE
3.3 yrs

Maarten Brusse

TITLE
Chief Commercial Officer of Asia
TENURE
2.6 yrs

Shane Smith

TITLE
Senior Vice President of Market Access & Reimbursement Oncimmune (Usa)
TENURE
2 yrs

Dan Calvo

TITLE
Senior Advisor
TENURE
3.1 yrs
Board of Directors Tenure

Average tenure and age of the Oncimmune Holdings board of directors in years:

2.5
Average Tenure
53
Average Age
  • The average tenure for the Oncimmune Holdings board of directors is less than 3 years, this suggests a new board.
Board of Directors

Meinhard Schmidt

TITLE
Non-Executive Chairman
COMPENSATION
£69K
AGE
57
TENURE
3.6 yrs

Adam Hill

TITLE
CEO & Director
COMPENSATION
£333K
AGE
38

Geoffrey Hamilton-Fairley

TITLE
Non-Executive Vice Chairman
COMPENSATION
£305K
TENURE
0.6 yrs

Richard Sharp

TITLE
Non Executive Director

Andrew Unitt

TITLE
Independent Non Executive Director
COMPENSATION
£18K
TENURE
5.3 yrs

Peter Johnston

TITLE
Chairman of Scientific Board
TENURE
0.3 yrs

Annalisa Jenkins

TITLE
Senior Independent Non-Executive Director
COMPENSATION
£15K
AGE
53

Julian Hirst

TITLE
Independent Non-Executive Director
COMPENSATION
£36K
AGE
59
TENURE
2.8 yrs

Carsten Schroeder

TITLE
Independent Non-Executive Director
AGE
52
TENURE
2.5 yrs

Cheung To

TITLE
Non-Executive Director
TENURE
0.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Oncimmune Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Oncimmune Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Oncimmune Holdings Plc, an early cancer detection company, develops and commercializes products to diagnose cancer in the United Kingdom and North America. The company engages in the development of autoantibody based platform to allow cancer detection to a range of solid cancer tumor types. It offers EarlyCDT-Lung, a blood test, which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. The company also develops EarlyCDT-Liver to aid in the detection and confirmation of hepatocellular carcinoma (HCC) in high-risk patients with liver lesions of all sizes tests for liver cancer. Oncimmune Holdings Plc was incorporated in 2015 and is headquartered in Nottingham, the United Kingdom.

Details
Name: Oncimmune Holdings Plc
OCY
Exchange: BST
Founded: 2015
£72,381,763
63,250,217
Website: http://www.oncimmune.com
Address: Oncimmune Holdings Plc
Clinical Sciences Building,
Nottingham City Hospital,
Nottingham,
Nottinghamshire, NG5 1PB,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM ONC Ordinary Shares London Stock Exchange AIM Market GB GBP 18. May 2016
BST OCY Ordinary Shares Boerse-Stuttgart DE EUR 18. May 2016
Number of employees
Current staff
Staff numbers
52
Oncimmune Holdings employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:53
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/19
Last earnings filing: 2019/02/13
Last earnings reported: 2018/11/30
Last annual earnings reported: 2018/05/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.